FDA’s Court Retort: Device PMA Approval Preempts State Common Law Claims
This article was originally published in The Gray Sheet
Executive Summary
State tort claims of device design defect, labeling, strict liability, negligence and failure to warn are preempted by PMA approval, the Department of Justice argues in a May brief filed on behalf of FDA
You may also be interested in...
Supreme Court Seeks Solicitor General’s Input On PMA Preemption
The U.S. Supreme Court is considering whether to hear a potentially far-reaching case on whether patients injured by PMA-approved devices can sue manufacturers under state laws
Supreme Court Seeks Solicitor General’s Input On PMA Preemption
The U.S. Supreme Court is considering whether to hear a potentially far-reaching case on whether patients injured by PMA-approved devices can sue manufacturers under state laws
Troy Advances Case For Preemption; Verdict On Liability Reform Still Pending
Product liability reform measures likely will have to include an alternative compensation program for injured consumers, former FDA Chief Counsel Daniel Troy said Jan. 26